Title | Diabetes in midlife and cognitive change over 20 years: a cohort study. |
Publication Type | Journal Article |
Year of Publication | 2014 |
Authors | Rawlings AM, Sharrett ARichey, Schneider ALC, Coresh JJ, Albert M, Couper DJ, Griswold M, Gottesman RF, Wagenknecht LE, B Windham G |
Secondary Authors | Selvin E |
Journal | Ann Intern Med |
Volume | 161 |
Issue | 11 |
Pagination | 785-93 |
Date Published | 2014 Dec 02 |
ISSN | 1539-3704 |
Keywords | African Americans, Aged, Cognition Disorders, Diabetes Mellitus, Type 2, European Continental Ancestry Group, Female, Glycated Hemoglobin A, Humans, Longitudinal Studies, Male, Middle Aged, Propensity Score, Prospective Studies, Risk Factors |
Abstract | BACKGROUND: Type 2 diabetes is associated with dementia risk, but evidence is limited for possible associations of diabetes and prediabetes with cognitive decline. OBJECTIVE: To determine whether diabetes in midlife is associated with 20-year cognitive decline and to characterize long-term cognitive decline across clinical categories of hemoglobin A1c (HbA1c) levels. DESIGN: Prospective cohort study. SETTING: The community-based ARIC (Atherosclerosis Risk in Communities) study. PARTICIPANTS: 13,351 black and white adults aged 48 to 67 years at baseline (1990 to 1992). MEASUREMENTS: Diabetes was defined by self-reported physician diagnosis or medication use or HbA1c level of 6.5% or greater. Undiagnosed diabetes, prediabetes, and glucose control in persons with diagnosed diabetes were defined by clinical categories of HbA1c level. Delayed word recall, digit symbol substitution, and word fluency tests were used to assess cognitive performance and were summarized with a global Z score. RESULTS: Diabetes in midlife was associated with a 19% greater cognitive decline over 20 years (adjusted global Z-score difference, -0.15 [;95% CI, -0.22 to -0.08];) compared with no diabetes. Cognitive decline was significantly greater among persons with prediabetes (HbA1c level of 5.7% to 6.4%) than among those with an HbA1c level less than 5.7%. Participants with poorly controlled diabetes (HbA1c level ≥ 7.0%) had greater decline than those whose diabetes was controlled (adjusted global Z-score difference, -0.16; P = 0.071). Longer-duration diabetes was also associated with greater late-life cognitive decline (P for trend LIMITATION: Single HbA1c measurement at baseline, 1 test per cognitive domain, and potential geographic confounding of race comparisons. CONCLUSION: Diabetes prevention and glucose control in midlife may protect against late-life cognitive decline. PRIMARY FUNDING SOURCE: National Institutes of Health. |
DOI | 10.7326/M14-0737 |
Alternate Journal | Ann Intern Med |
PubMed ID | 25437406 |
PubMed Central ID | PMC4432464 |
Grant List | HHSN268201100012C / HL / NHLBI NIH HHS / United States HHSN268201100009I / HL / NHLBI NIH HHS / United States HL096899 / HL / NHLBI NIH HHS / United States U01 HL096812 / HL / NHLBI NIH HHS / United States HHSN268201100010C / HL / NHLBI NIH HHS / United States HL096902 / HL / NHLBI NIH HHS / United States HHSN268201100008C / HL / NHLBI NIH HHS / United States HHSN268201100005G / HL / NHLBI NIH HHS / United States U01 HL096917 / HL / NHLBI NIH HHS / United States HHSN268201100008I / HL / NHLBI NIH HHS / United States HHSN268201100005C / / PHS HHS / United States R01 DK089174 / DK / NIDDK NIH HHS / United States HHSN268201100007C / HL / NHLBI NIH HHS / United States HL096917 / HL / NHLBI NIH HHS / United States HHSN268201100009C / / PHS HHS / United States R01DK089174 / DK / NIDDK NIH HHS / United States HHSN268201100011I / HL / NHLBI NIH HHS / United States HHSN268201100011C / HL / NHLBI NIH HHS / United States U01 HL096902 / HL / NHLBI NIH HHS / United States T32 HL007024 / HL / NHLBI NIH HHS / United States R01 AG040282 / AG / NIA NIH HHS / United States HHSN268201100010C / / PHS HHS / United States R01HL70825 / HL / NHLBI NIH HHS / United States HHSN268201100006C / HL / NHLBI NIH HHS / United States HHSN268201100008C / / PHS HHS / United States HHSN268201100012C / / PHS HHS / United States HL096814 / HL / NHLBI NIH HHS / United States HHSN268201100005I / HL / NHLBI NIH HHS / United States U01HL096812 / HL / NHLBI NIH HHS / United States U01 HL096814 / HL / NHLBI NIH HHS / United States T32HL007024 / HL / NHLBI NIH HHS / United States HHSN268201100007C / / PHS HHS / United States HHSN268201100009C / HL / NHLBI NIH HHS / United States R01 HL070825 / HL / NHLBI NIH HHS / United States HHSN268201100011C / / PHS HHS / United States HHSN268201100005C / HL / NHLBI NIH HHS / United States U01 HL096899 / HL / NHLBI NIH HHS / United States HHSN268201100007I / HL / NHLBI NIH HHS / United States HHSN268201100006C / / PHS HHS / United States R01AG040282 / AG / NIA NIH HHS / United States |